Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Fuji
Cantor Fitzgerald
AstraZeneca
US Army
McKesson
Colorcon
UBS
Chinese Patent Office

Generated: December 15, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR STRONTIUM CHLORIDE SR-89

« Back to Dashboard

Clinical Trials for Strontium Chloride Sr-89

Trial ID Title Status Sponsor Phase Summary
NCT00024167 Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer Terminated National Cancer Institute (NCI) Phase 3 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radioactive substances such as strontium-89 may relieve bone pain associated with prostate cancer. It is not yet known whether chemotherapy is more effective with or without strontium-89 in treating bone metastases. PURPOSE: This randomized phase III trial is studying giving chemotherapy together with strontium-89 to see how well it works compared to chemotherapy alone in treating patients with prostate cancer that has spread to the bone.
NCT00024167 Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer Terminated M.D. Anderson Cancer Center Phase 3 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radioactive substances such as strontium-89 may relieve bone pain associated with prostate cancer. It is not yet known whether chemotherapy is more effective with or without strontium-89 in treating bone metastases. PURPOSE: This randomized phase III trial is studying giving chemotherapy together with strontium-89 to see how well it works compared to chemotherapy alone in treating patients with prostate cancer that has spread to the bone.
NCT00080782 Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases Terminated National Cancer Institute (NCI) Phase 2 RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Strontium-89 may relieve bone pain caused by prostate cancer. Celecoxib may stop the growth of cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth. Combining doxorubicin and strontium-89 with celecoxib may kill more tumor cells. PURPOSE: This randomized phase II trial is studying celecoxib together with doxorubicin and strontium-89 to see how well they work compared to doxorubicin and strontium-89 alone in treating patients with progressive androgen-independent prostate cancer and bone metastases.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Strontium Chloride Sr-89

Condition Name

Condition Name for Strontium Chloride Sr-89
Intervention Trials
Prostate Cancer 5
Metastatic Cancer 4
Pain 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Strontium Chloride Sr-89
Intervention Trials
Prostatic Neoplasms 5
Neoplasm Metastasis 4
Osteoarthritis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Strontium Chloride Sr-89

Trials by Country

Trials by Country for Strontium Chloride Sr-89
Location Trials
United States 48
United Kingdom 5
Germany 3
Norway 2
Russian Federation 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Strontium Chloride Sr-89
Location Trials
Texas 3
Ohio 2
Illinois 2
Iowa 2
Mississippi 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Strontium Chloride Sr-89

Clinical Trial Phase

Clinical Trial Phase for Strontium Chloride Sr-89
Clinical Trial Phase Trials
Phase 3 3
Phase 2/Phase 3 1
Phase 2 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Strontium Chloride Sr-89
Clinical Trial Phase Trials
Completed 6
Terminated 2
Unknown status 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Strontium Chloride Sr-89

Sponsor Name

Sponsor Name for Strontium Chloride Sr-89
Sponsor Trials
National Cancer Institute (NCI) 4
SantoSolve AS 3
M.D. Anderson Cancer Center 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Strontium Chloride Sr-89
Sponsor Trials
Other 13
NIH 4
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Farmers Insurance
Medtronic
Accenture
Harvard Business School
Boehringer Ingelheim
US Department of Justice
Teva
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.